Clinical Trial Update: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on belimumab for systemic sclerosis-associated interstitial lung disease, spanning Phase 2 and Phase 3, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | Phase 2, Phase 3 | Status: RECRUITING